New gene therapy trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07075185
Summary
This early-stage trial is testing the safety of a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or stopped responding to other treatments. The therapy works by modifying the patient's own immune cells inside the body to better target cancer cells. Researchers will enroll 40 participants to determine the safest dose and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Alfred Paula Fox Melanoma and Cancer Centre
RECRUITINGMelbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Prince Alfred
RECRUITINGCamperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.